The ‘monopolistic’ brain tumor treatment ‘Temodal’ will face 3-way competition against domestic pharmaceutical products
As a domestic pharmaceutical company entered the MSD’s brain tumor treatment ‘Temodal(temozolomide)’ market, the 3-way competition is expected to be formed.
Temodal was expired in patent on December 2011, but has taken a monopolistic position due to difficulties in its development.(the domestic ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
